ST. JOSEPH ASPIRIN EC (aspirin)
LOW DOSE ASPIRIN (81 MG OR LESS)·MYOCARDIAL REINFARCTION PREVENTION·+11
FOUNDATION CONS
Indication
Thrombosis prevention after percutaneous coronary intervention
Thrombosis prevention after percutaneous coronary intervention refers to prophylactic antithrombotic management aimed at preventing acute, subacute, or late thrombotic vessel occlusion in patients who have undergone transcatheter coronary revascularization. Read more about Thrombosis prevention after percutaneous coronary intervention
227 drugs 130 manufacturers
Drugs that treat it
Common Thrombosis prevention after percutaneous coronary intervention therapies.
ASPIRIN EC (aspirin)
NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES·MYOCARDIAL REINFARCTION PREVENTION·+11
RELIABLE 1 LABO
ASPIRIN EC (aspirin)
LOW DOSE ASPIRIN (81 MG OR LESS)·MYOCARDIAL REINFARCTION PREVENTION·+11
AKRON PHARMA IN
ASPIRIN EC (aspirin)
LOW DOSE ASPIRIN (81 MG OR LESS)·MYOCARDIAL REINFARCTION PREVENTION·+11
AACE PHARMACEUT
ASPIRIN EC (aspirin)
NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES·MYOCARDIAL REINFARCTION PREVENTION·+11
APHENA PHARMA S
CLOPIDOGREL (clopidogrel bisulfate)
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW·MYOCARDIAL REINFARCTION PREVENTION·+4
APHENA PHARMA S
CLOPIDOGREL (clopidogrel bisulfate)
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW·MYOCARDIAL REINFARCTION PREVENTION·+4
NOVADOZ PHARMAC
CLOPIDOGREL (clopidogrel bisulfate)
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW·MYOCARDIAL REINFARCTION PREVENTION·+4
RADHA PHARMACEU
ASPIRIN EC (aspirin)
LOW DOSE ASPIRIN (81 MG OR LESS)·MYOCARDIAL REINFARCTION PREVENTION·+11
NOBLE OTC LLC
Filter & compare in the drug finder →Opens the drug finder with Thrombosis prevention after percutaneous coronary intervention preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThrombosis prevention after percutaneous coronary intervention refers to prophylactic antithrombotic management aimed at preventing acute, subacute, or late thrombotic vessel occlusion in patients who have undergone transcatheter coronary revascularization.
Following balloon angioplasty and coronary stent implantation, mechanical endothelial disruption, exposed subendothelial matrix, and foreign metallic or polymer surfaces create a highly prothrombotic environment in the coronary vasculature.
Left unmitigated, platelet adhesion, activation, and thrombin generation can lead to sudden stent thrombosis or recurrent ischemic coronary events, which typically manifest as acute myocardial infarction or cardiovascular death.
- nih.gov
Thrombosis prevention after percutaneous coronary intervention refers to prophylactic antithrombotic management aimed at preventing acute, subacute, or late thrombotic vessel occlusion in patients who have undergone transcatheter coronary revascularization
- nih.gov
Thrombosis prevention after percutaneous coronary intervention refers to prophylactic antithrombotic management aimed at preventing acute, subacute, or late thrombotic vessel occlusion in patients who have undergone transcatheter coronary revascularization Left unmitigated, platelet adhesion, activation, and thrombin generation can lead to sudden stent thrombosis or recurrent ischemic coronary events, which typically manifest as acute myocardial infarction or cardiovascular death
- nih.gov
Thrombosis prevention after percutaneous coronary intervention refers to prophylactic antithrombotic management aimed at preventing acute, subacute, or late thrombotic vessel occlusion in patients who have undergone transcatheter coronary revascularization
- nih.gov
Following balloon angioplasty and coronary stent implantation, mechanical endothelial disruption, exposed subendothelial matrix, and foreign metallic or polymer surfaces create a highly prothrombotic environment in the coronary vasculature Left unmitigated, platelet adhesion, activation, and thrombin generation can lead to sudden stent thrombosis or recurrent ischemic coronary events, which typically manifest as acute myocardial infarction or cardiovascular death
- escardio.org
Following balloon angioplasty and coronary stent implantation, mechanical endothelial disruption, exposed subendothelial matrix, and foreign metallic or polymer surfaces create a highly prothrombotic environment in the coronary vasculature Left unmitigated, platelet adhesion, activation, and thrombin generation can lead to sudden stent thrombosis or recurrent ischemic coronary events, which typically manifest as acute myocardial infarction or cardiovascular death
- nih.gov
Left unmitigated, platelet adhesion, activation, and thrombin generation can lead to sudden stent thrombosis or recurrent ischemic coronary events, which typically manifest as acute myocardial infarction or cardiovascular death
Personalize your experience
Follow Thrombosis prevention after percutaneous coronary intervention and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.